Lymphoma hub
@lymphomahub.bsky.social
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia.
🚨 News 🚨
@US_FDA grants 510(k) clearance to a novel automated mass‑spectrometry system to aid in diagnosis of multiple myeloma and related disorders, including #WaldenstromsMacroglobulinemia. The platform detects and isotypes M-proteins with high sensitivity.
Read more: https://loom.ly/V5rp6VU
@US_FDA grants 510(k) clearance to a novel automated mass‑spectrometry system to aid in diagnosis of multiple myeloma and related disorders, including #WaldenstromsMacroglobulinemia. The platform detects and isotypes M-proteins with high sensitivity.
Read more: https://loom.ly/V5rp6VU
November 14, 2025 at 3:57 PM
🚨 News 🚨
@US_FDA grants 510(k) clearance to a novel automated mass‑spectrometry system to aid in diagnosis of multiple myeloma and related disorders, including #WaldenstromsMacroglobulinemia. The platform detects and isotypes M-proteins with high sensitivity.
Read more: https://loom.ly/V5rp6VU
@US_FDA grants 510(k) clearance to a novel automated mass‑spectrometry system to aid in diagnosis of multiple myeloma and related disorders, including #WaldenstromsMacroglobulinemia. The platform detects and isotypes M-proteins with high sensitivity.
Read more: https://loom.ly/V5rp6VU
New publication📝 Results from an analysis of PROs from the POLARIX trial, published in Blood, highlight the value of patient-centric tools alongside clinician assessments for evaluating treatment tolerability.
Learn more: https://loom.ly/BB_Azos
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/BB_Azos
#lymphoma #lymsm #MedNews #MedEd
November 14, 2025 at 9:01 AM
New publication📝 Results from an analysis of PROs from the POLARIX trial, published in Blood, highlight the value of patient-centric tools alongside clinician assessments for evaluating treatment tolerability.
Learn more: https://loom.ly/BB_Azos
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/BB_Azos
#lymphoma #lymsm #MedNews #MedEd
🚨 NEWS 🚨
FDA grants RMAT designation to MB-105, a first-in-class autologous CD5-targeted CAR T-cell therapy, for the treatment of patients with CD5+ R/R T-cell lymphoma.
Read more: https://loom.ly/uy1jSxg
#lymsm #Lymphoma #MedNews #MedEd
FDA grants RMAT designation to MB-105, a first-in-class autologous CD5-targeted CAR T-cell therapy, for the treatment of patients with CD5+ R/R T-cell lymphoma.
Read more: https://loom.ly/uy1jSxg
#lymsm #Lymphoma #MedNews #MedEd
November 12, 2025 at 4:08 PM
🚨 NEWS 🚨
FDA grants RMAT designation to MB-105, a first-in-class autologous CD5-targeted CAR T-cell therapy, for the treatment of patients with CD5+ R/R T-cell lymphoma.
Read more: https://loom.ly/uy1jSxg
#lymsm #Lymphoma #MedNews #MedEd
FDA grants RMAT designation to MB-105, a first-in-class autologous CD5-targeted CAR T-cell therapy, for the treatment of patients with CD5+ R/R T-cell lymphoma.
Read more: https://loom.ly/uy1jSxg
#lymsm #Lymphoma #MedNews #MedEd
New publication📝 Results from a phase Ib/II trial, published in the Journal of Clinical Oncology, show Glofit-Pola achieved 78.3% ORR in heavily pretreated R/R LBCL, including patients with HGBCL and previous CAR T-cell therapy.
Learn more: https://loom.ly/rC-uX7Y
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/rC-uX7Y
#lymphoma #lymsm #MedNews #MedEd
November 10, 2025 at 9:01 AM
New publication📝 Results from a phase Ib/II trial, published in the Journal of Clinical Oncology, show Glofit-Pola achieved 78.3% ORR in heavily pretreated R/R LBCL, including patients with HGBCL and previous CAR T-cell therapy.
Learn more: https://loom.ly/rC-uX7Y
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/rC-uX7Y
#lymphoma #lymsm #MedNews #MedEd
Francesc Bosch discussed factors influencing fixed-duration BTKi + BCL-2i treatment selection for patients with CLL.
Listen here: https://loom.ly/rOxk8hM
#leusm #lymsm #MedNews #MedEd
Listen here: https://loom.ly/rOxk8hM
#leusm #lymsm #MedNews #MedEd
November 7, 2025 at 3:07 PM
Francesc Bosch discussed factors influencing fixed-duration BTKi + BCL-2i treatment selection for patients with CLL.
Listen here: https://loom.ly/rOxk8hM
#leusm #lymsm #MedNews #MedEd
Listen here: https://loom.ly/rOxk8hM
#leusm #lymsm #MedNews #MedEd
New publication📝2-year follow-up results from the RELIANCE trial, published in The British Journal of Haematology, show that relma-cel was associated with a CR rate of 96.3% in patients with R/R FL.
Learn more: https://loom.ly/uiZeapw
#lymphoma #CART #lymsm #MedNews #MedEd
Learn more: https://loom.ly/uiZeapw
#lymphoma #CART #lymsm #MedNews #MedEd
November 7, 2025 at 11:01 AM
Francesc Bosch discussed factors influencing the use of fixed-duration therapy for patients with CLL.
Watch the full video here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Watch the full video here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
November 6, 2025 at 5:30 PM
Francesc Bosch discussed factors influencing the use of fixed-duration therapy for patients with CLL.
Watch the full video here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Watch the full video here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
New data 📝 Results from studies of real-world outcomes and CD19 expression following tafasitamab treatment in patients with R/R DLBCL may guide the sequencing of CD19-directed therapies in this patient population.
Learn more: https://loom.ly/6s-ODz0
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/6s-ODz0
#lymphoma #lymsm #MedNews #MedEd
November 5, 2025 at 9:01 AM
New data 📝 Results from studies of real-world outcomes and CD19 expression following tafasitamab treatment in patients with R/R DLBCL may guide the sequencing of CD19-directed therapies in this patient population.
Learn more: https://loom.ly/6s-ODz0
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/6s-ODz0
#lymphoma #lymsm #MedNews #MedEd
New publication 📝 Results from the phase II FIL_V-RBAC trial, published in Lancet Haematology, show venetoclax added to RBAC was associated with a 2-year PFS rate of 60% in older patients with high-risk MCL.
Learn more: https://loom.ly/EiJNbmg
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/EiJNbmg
#lymphoma #lymsm #MedNews #MedEd
November 3, 2025 at 9:01 AM
New publication 📝 Results from the phase II FIL_V-RBAC trial, published in Lancet Haematology, show venetoclax added to RBAC was associated with a 2-year PFS rate of 60% in older patients with high-risk MCL.
Learn more: https://loom.ly/EiJNbmg
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/EiJNbmg
#lymphoma #lymsm #MedNews #MedEd
What factors influence BTKi + BCL-2i treatment selection for patients with CLL? The Lymphoma Hub was pleased to speak to Francesc Bosch, University Hospital Vall d’Hebron, about the use of fixed-duration therapy in CLL.
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
October 31, 2025 at 12:04 PM
What factors influence BTKi + BCL-2i treatment selection for patients with CLL? The Lymphoma Hub was pleased to speak to Francesc Bosch, University Hospital Vall d’Hebron, about the use of fixed-duration therapy in CLL.
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
New publication 📝 Phase II/II ENRICH trial results, published in The Lancet, show ibrutinib + rituximab improves PFS vs immunochemotherapy in older patients with previously untreated MCL (HR, 0.69; 95% CI, 0.52–0.90; p = 0.0034).
Learn more: LymphomaHub.com
#lymsm #lymphoma #MedNews #MedEd
Learn more: LymphomaHub.com
#lymsm #lymphoma #MedNews #MedEd
October 31, 2025 at 9:01 AM
Francesc Bosch, University Hospital Vall d’Hebron, discussed factors influencing BTKi + BCL-2i treatment selection for patients with CLL.
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
October 29, 2025 at 11:02 PM
Francesc Bosch, University Hospital Vall d’Hebron, discussed factors influencing BTKi + BCL-2i treatment selection for patients with CLL.
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
New publication 📝 Results from the phase III SUNMO trial, published in the Journal of Clinical Oncology, show Mosun-Pola significantly improved PFS (11.5 vs 3.8 months) and ORR (70% vs 40%) vs R-GemOx in transplant-ineligible R/R LBCL.
Learn more: LymphomaHub.com
#lymsm #lymphoma #MedNews #MedEd
Learn more: LymphomaHub.com
#lymsm #lymphoma #MedNews #MedEd
October 28, 2025 at 9:01 AM
New publication📝Phase II results, published in Blood, show zanubrutinib + rituximab + lenalidomide was associated with a 65% CR rate, 2-year PFS of 67.1%, and 2-year OS of 82.4% in patients aged ≥75 years with de novo DLBCL.
Learn more: LymphomaHub.com
#DLBCL #lymphoma #lymsm #MedNews #MedEd
Learn more: LymphomaHub.com
#DLBCL #lymphoma #lymsm #MedNews #MedEd
October 24, 2025 at 8:01 AM
New publication 📝 Data published in The Journal of Clinical Oncology show ctDNA detection at EOT strongly predicts outcomes in LBCL, with detectable ctDNA MRD associated with 2-year PFS of 29% vs 97% for undetectable MRD.
Learn more: LymphomaHub.com
#lymphoma #lymsm #ctDNA #MedNews #MedEd
Learn more: LymphomaHub.com
#lymphoma #lymsm #ctDNA #MedNews #MedEd
October 21, 2025 at 10:01 AM
Charles Herbaux, University of Montpellier, discusses the 2L and 3L+ data from the randomized phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL.
Watch the full video here: https://loom.ly/FdLag2Q
#lymsm #lymphoma #MedNews #MedEd
Watch the full video here: https://loom.ly/FdLag2Q
#lymsm #lymphoma #MedNews #MedEd
October 17, 2025 at 1:31 PM
Charles Herbaux, University of Montpellier, discusses the 2L and 3L+ data from the randomized phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL.
Watch the full video here: https://loom.ly/FdLag2Q
#lymsm #lymphoma #MedNews #MedEd
Watch the full video here: https://loom.ly/FdLag2Q
#lymsm #lymphoma #MedNews #MedEd
New publication 📝 Phase III results, published in Blood, show acalabrutinib + obinutuzumab significantly improved PFS and OS vs chlorambucil + obinutuzumab in treatment-naïve CLL (72-month PFS, 78.0% vs 17.2%; p < 0.0001).
Learn more: LymphomaHub.com
#CLLsm #leusm #MedNews #MedEd
Learn more: LymphomaHub.com
#CLLsm #leusm #MedNews #MedEd
October 17, 2025 at 8:01 AM
🚨 NEWS 🚨
FDA grants fast track designation to EO2463, an ‘OncoMimic’ immunotherapy, for the treatment of patients with FL in the low tumor burden “watch-and-wait” setting.
Read more: https://loom.ly/jx-bpb4
#lymsm #lymphoma #MedNews #MedEd
FDA grants fast track designation to EO2463, an ‘OncoMimic’ immunotherapy, for the treatment of patients with FL in the low tumor burden “watch-and-wait” setting.
Read more: https://loom.ly/jx-bpb4
#lymsm #lymphoma #MedNews #MedEd
October 16, 2025 at 4:06 PM
🚨 NEWS 🚨
FDA grants fast track designation to EO2463, an ‘OncoMimic’ immunotherapy, for the treatment of patients with FL in the low tumor burden “watch-and-wait” setting.
Read more: https://loom.ly/jx-bpb4
#lymsm #lymphoma #MedNews #MedEd
FDA grants fast track designation to EO2463, an ‘OncoMimic’ immunotherapy, for the treatment of patients with FL in the low tumor burden “watch-and-wait” setting.
Read more: https://loom.ly/jx-bpb4
#lymsm #lymphoma #MedNews #MedEd
Charles Herbaux, University of Montpellier, discusses the 2L and 3L+ data from the phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL.
Listen here: https://loom.ly/1ncUMzw
#lymsm #lymphoma #MedNews #MedEd
Listen here: https://loom.ly/1ncUMzw
#lymsm #lymphoma #MedNews #MedEd
October 15, 2025 at 5:03 PM
Charles Herbaux, University of Montpellier, discusses the 2L and 3L+ data from the phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL.
Listen here: https://loom.ly/1ncUMzw
#lymsm #lymphoma #MedNews #MedEd
Listen here: https://loom.ly/1ncUMzw
#lymsm #lymphoma #MedNews #MedEd
New publication 📝 Results from the phase II COALITION, published in Journal of Clinical Oncology, show glofitamab in combination with R-CHOP or Pola-R-CHP was feasible and safe, with durable responses in patients with LBCL.
Learn more: LymphomaHub.com
#Lymphoma #lymsm #MedNews #MedEd
Learn more: LymphomaHub.com
#Lymphoma #lymsm #MedNews #MedEd
October 15, 2025 at 2:06 PM
🚨 NEWS 🚨
FDA grants breakthrough therapy designation to sonrotoclax, a next-generation BCL-2 inhibitor, for the treatment of R/R MCL, based on results from the BGB-11417-201 trial.
Read more: https://loom.ly/AfWxP3A
#lymsm #leusm #MedNews #MedEd
FDA grants breakthrough therapy designation to sonrotoclax, a next-generation BCL-2 inhibitor, for the treatment of R/R MCL, based on results from the BGB-11417-201 trial.
Read more: https://loom.ly/AfWxP3A
#lymsm #leusm #MedNews #MedEd
October 14, 2025 at 3:22 PM
🚨 NEWS 🚨
FDA grants breakthrough therapy designation to sonrotoclax, a next-generation BCL-2 inhibitor, for the treatment of R/R MCL, based on results from the BGB-11417-201 trial.
Read more: https://loom.ly/AfWxP3A
#lymsm #leusm #MedNews #MedEd
FDA grants breakthrough therapy designation to sonrotoclax, a next-generation BCL-2 inhibitor, for the treatment of R/R MCL, based on results from the BGB-11417-201 trial.
Read more: https://loom.ly/AfWxP3A
#lymsm #leusm #MedNews #MedEd
New data 📝 At #EHA2025 and #18ICML, Matthew Ku and Krish Patel, respectively, presented results from a phase Ib study investigating JNJ-90014496, a CD19/CD20 bispecific CAR T-cell therapy, in patients with R/R LBCL.
Learn more: https://loom.ly/bobViGE
#Lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/bobViGE
#Lymphoma #lymsm #MedNews #MedEd
October 13, 2025 at 11:01 AM
New publication 📝 Phase I/II results, published in Blood Advances, show pirtobrutinib achieved 52.1% ORR in patients with R/R FL, with median DoR of 10.2 months and favorable tolerability.
Learn more: https://loom.ly/DEFIgFo
#lymsm #lymphoma #MedNews #MedEd
Learn more: https://loom.ly/DEFIgFo
#lymsm #lymphoma #MedNews #MedEd
October 13, 2025 at 8:01 AM
New publication 📝 Phase I/II results, published in Blood Advances, show pirtobrutinib achieved 52.1% ORR in patients with R/R FL, with median DoR of 10.2 months and favorable tolerability.
Learn more: https://loom.ly/DEFIgFo
#lymsm #lymphoma #MedNews #MedEd
Learn more: https://loom.ly/DEFIgFo
#lymsm #lymphoma #MedNews #MedEd
What are the latest updates from the phase III STARGLO trial? The Lymphoma Hub spoke to Charles Herbaux, University of Montpellier, about the 2L and 3L+ data from this trial.
Watch here: https://loom.ly/FdLag2Q
#lymsm #lymphoma #MedNews #MedEd
Watch here: https://loom.ly/FdLag2Q
#lymsm #lymphoma #MedNews #MedEd
October 9, 2025 at 8:01 AM
What are the latest updates from the phase III STARGLO trial? The Lymphoma Hub spoke to Charles Herbaux, University of Montpellier, about the 2L and 3L+ data from this trial.
Watch here: https://loom.ly/FdLag2Q
#lymsm #lymphoma #MedNews #MedEd
Watch here: https://loom.ly/FdLag2Q
#lymsm #lymphoma #MedNews #MedEd